Michelle B Nadler1, Alexandra Desnoyers2, David M Langelier3, Eitan Amir4. 1. Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada. Electronic address: michelle.nadler@uhn.ca. 2. Department of Medicine, Centre Hospitalier Universitaire de Sherbrooke and the University of Sherbrooke, Sherbrooke, Quebec, Canada. 3. Division of Physical Medicine and Rehabilitation, Department of Medicine, Toronto Rehabilitation Institute and the University of Toronto, Toronto, Ontario, Canada. 4. Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: People with metastatic cancers experience poor quality of life (QoL), fatigue, and decreased physical function. Exercise improves these symptoms in the curative setting, but the efficacy and safety of exercise in the metastatic setting is uncertain. METHODS: Prospective, randomized trials of moderate/high-intensity aerobic exercise or resistance training vs. control in patients with advanced/metastatic solid cancers were identified from prior reviews and updated using a search of PubMed. The mean and SD for validated outcome measures (QoL, physical function, and fatigue) were extracted for intervention and control groups at baseline and postintervention. The Mann-Whitney test was used to evaluate the effect of exercise on the pooled change between baseline and postintervention. Safety was evaluated qualitatively. RESULTS: Sixteen trials were analyzed. Among patients with scores at the mean or 2SD above, exercise was not associated with significant or clinical difference in QoL or fatigue. In patients with baseline scores 2SD below mean, exercise was associated with nonsignificant difference meeting minimal clinical important difference in QoL (-2.8 vs. 4.6, P = 0.28). For function, patients at the mean had nonstatistically significant, but clinically meaningful difference in the six-minute walk test (6-MWT) (14.7 vs. 29.0 m, P = 0.44). In patients 2 SD below the mean, there was a clinically meaningful difference in two patient-reported functional subscales (0.1 vs. 5.3, P = 0.076 and 0.44 vs. 8.5, P = 0.465) and a clinically meaningful improvement in the 6-MWT (-7.5 vs. 27.0 m, P = 0.34), although none of these associations met statistical significance. There were no differences in falls, fractures, or pain. DISCUSSION: Exercise is associated with clinically meaningful improvements in QoL, function, and 6-MWT in some patients with metastatic cancer. Despite poor reporting of safety, there was no signal of increased harm from exercise in this setting.
BACKGROUND:People with metastatic cancers experience poor quality of life (QoL), fatigue, and decreased physical function. Exercise improves these symptoms in the curative setting, but the efficacy and safety of exercise in the metastatic setting is uncertain. METHODS: Prospective, randomized trials of moderate/high-intensity aerobic exercise or resistance training vs. control in patients with advanced/metastatic solid cancers were identified from prior reviews and updated using a search of PubMed. The mean and SD for validated outcome measures (QoL, physical function, and fatigue) were extracted for intervention and control groups at baseline and postintervention. The Mann-Whitney test was used to evaluate the effect of exercise on the pooled change between baseline and postintervention. Safety was evaluated qualitatively. RESULTS: Sixteen trials were analyzed. Among patients with scores at the mean or 2SD above, exercise was not associated with significant or clinical difference in QoL or fatigue. In patients with baseline scores 2SD below mean, exercise was associated with nonsignificant difference meeting minimal clinical important difference in QoL (-2.8 vs. 4.6, P = 0.28). For function, patients at the mean had nonstatistically significant, but clinically meaningful difference in the six-minute walk test (6-MWT) (14.7 vs. 29.0 m, P = 0.44). In patients 2 SD below the mean, there was a clinically meaningful difference in two patient-reported functional subscales (0.1 vs. 5.3, P = 0.076 and 0.44 vs. 8.5, P = 0.465) and a clinically meaningful improvement in the 6-MWT (-7.5 vs. 27.0 m, P = 0.34), although none of these associations met statistical significance. There were no differences in falls, fractures, or pain. DISCUSSION: Exercise is associated with clinically meaningful improvements in QoL, function, and 6-MWT in some patients with metastatic cancer. Despite poor reporting of safety, there was no signal of increased harm from exercise in this setting.
Authors: Marta K Mikkelsen; Cecilia M Lund; Anders Vinther; Anders Tolver; Julia S Johansen; Inna Chen; Anne-Mette Ragle; Bo Zerahn; Lotte Engell-Noerregaard; Finn O Larsen; Susann Theile; Dorte L Nielsen; Mary Jarden Journal: Oncologist Date: 2022-02-03 Impact factor: 5.837
Authors: Inger Utne; Bruce A Cooper; Christine Ritchie; Melisa Wong; Laura B Dunn; Borghild Loyland; Ellen Karine Grov; Marilyn J Hammer; Steven M Paul; Jon D Levine; Yvette P Conley; Kord M Kober; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2020-08-03 Impact factor: 2.398
Authors: Alexander Haussmann; Nadine Ungar; Angeliki Tsiouris; Monika Sieverding; Joachim Wiskemann; Karen Steindorf Journal: Int J Behav Med Date: 2020-02
Authors: Donald R Sullivan; Mary E Medysky; Anna L Tyzik; Nathan F Dieckmann; Quin E Denfeld; Kerri Winters-Stone Journal: Psychooncology Date: 2021-02-04 Impact factor: 3.894
Authors: Hao Luo; Daniel A Galvão; Robert U Newton; Pedro Lopez; Colin Tang; Ciaran M Fairman; Nigel Spry; Dennis R Taaffe Journal: Pancreas Date: 2021-03-01 Impact factor: 3.243
Authors: Emma J Chapman; Erica Di Martino; Zoe Edwards; Kathryn Black; Matthew Maddocks; Michael I Bennett Journal: Palliat Med Date: 2021-12-14 Impact factor: 4.762
Authors: Youness Azemmour; Saber Boutayeb; Said Nafai; Amine Souadka; Hind Mrabti; Ibrahim Elghissassi; Abdelghafour Marfak; Hassan Errihani Journal: Pan Afr Med J Date: 2022-01-20